Hydroxychloroquine, sold under the brand name Plaquenil, is a genuine, FDA-approved treatment for certain forms of malaria — a fact that has become confused in the public mind after years of unrelated controversy over its other uses. This article sets aside that noise and answers the narrower, older, and better-established question: what does the evidence show about hydroxychloroquine as a malaria drug, how is it dosed, which malaria infections it can and cannot treat, and what should a patient reasonably expect from it.

What malaria actually is

Malaria is caused by single-celled parasites of the genus Plasmodium, transmitted to humans through the bite of an infected female Anopheles mosquito. Five species infect humans regularly: Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and, less commonly, P. knowlesi. Falciparum causes the most severe disease and nearly all malaria deaths; vivax and ovale can lie dormant in the liver for months or years before causing relapse.

Symptoms typically begin one to four weeks after the infective bite: high fever, chills and sweats, headache, muscle aches, fatigue, and gastrointestinal upset, often arriving in cycles as successive waves of parasites burst from infected red blood cells. Severe falciparum malaria can progress to organ failure, seizures, severe anemia, and death within days, which is why the World Health Organization has continued to report several hundred thousand malaria deaths globally each year, the great majority in sub-Saharan African children. Malaria is a medical emergency until proven otherwise in anyone with a compatible travel history and fever; it is not something to self-diagnose or self-treat at home.

Where hydroxychloroquine fits, and where it doesn't

Hydroxychloroquine is a 4-aminoquinoline, chemically related to chloroquine, both of which descend from quinine — the alkaloid extracted from the bark of the South American cinchona tree that missionaries and physicians used against fevers centuries before anyone understood parasites or pharmacology. It is a fair thing to note, in an age of synthetic chemistry, that one of medicine's oldest and most useful malaria treatments came directly out of the created world, refined by patient observation long before the mechanism was known.

The mechanism, now well described, is that the parasite digests hemoglobin inside infected red blood cells and must detoxify the resulting heme by converting it into an inert crystal called hemozoin. Hydroxychloroquine concentrates inside the parasite's digestive vacuole, raises its pH, and interferes with this detoxification process, causing toxic heme to accumulate and kill the parasite. This mechanism is well supported by laboratory and biochemical studies going back decades.

The critical limitation is resistance. Hydroxychloroquine and chloroquine are only reliably effective against P. vivax, P. ovale, P. malariae, and P. falciparum strains that remain chloroquine-sensitive. Chloroquine-resistant falciparum malaria was first documented in Southeast Asia and South America in the late 1950s and 1960s and has since spread through most of sub-Saharan Africa and other endemic regions. In areas with resistant falciparum, hydroxychloroquine simply does not clear the infection reliably, and using it there is not a matter of dosing more carefully — it does not work against those parasites. The U.S. Centers for Disease Control and Prevention accordingly restricts chloroquine and hydroxychloroquine use, for both treatment and prevention, to the shrinking list of regions without documented falciparum resistance, along with vivax, ovale, and malariae infections generally. For chloroquine-resistant falciparum malaria, the current standard of care worldwide is artemisinin-based combination therapy, and severe malaria requires hospital-level care, sometimes with intravenous artesunate.

The evidence base

Chloroquine's efficacy against sensitive malaria strains is one of the best-established findings in twentieth-century medicine, built on decades of clinical use, field trials, and pharmacokinetic study across military, colonial, and public-health medicine from the 1940s onward. Hydroxychloroquine was developed as a less toxic analogue in the 1950s and has been shown in comparative human trials to have essentially equivalent antimalarial efficacy to chloroquine against sensitive strains, with a somewhat better side-effect profile, which is part of why it has remained on national formularies and the WHO Model List of Essential Medicines for malaria even as chloroquine use has declined in some regions.

What is not supported is any claim that hydroxychloroquine can substitute for artemisinin-based therapy against resistant falciparum malaria, or that higher doses can overcome resistance — resistance in this context reflects genetic mutations in the parasite's transporter proteins, not a simple dose threshold. It is also worth being precise that hydroxychloroquine, like chloroquine, does not eliminate the dormant liver-stage forms (hypnozoites) of P. vivax and P. ovale. A patient treated successfully for the blood-stage infection can still relapse weeks or months later unless a second drug — primaquine or, more recently, tafenoquine — is given for what is called radical cure, after screening for G6PD deficiency, since these drugs can cause severe hemolysis in people who lack that enzyme.

Dosing for malaria

Hydroxychloroquine for malaria is dosed differently from the once-daily regimens used for lupus or rheumatoid arthritis, and it is a prescription medicine to be used under a physician's supervision, ideally guided by a confirmed blood test showing which Plasmodium species is present.

These figures are the standard reference doses; actual prescriptions should always follow the treating physician's assessment of the patient's weight, kidney and liver function, pregnancy status, other medications, and the specific Plasmodium species and region involved. Hydroxychloroquine is one of the few antimalarials generally considered acceptable in pregnancy, which matters directly to expectant mothers who need effective treatment without exposing an unborn child to a drug of greater concern — protecting both patients in that relationship is a legitimate part of choosing the right regimen.

What to expect during treatment

When hydroxychloroquine is used against a genuinely sensitive strain, most patients notice fever and symptom improvement within one to two days of starting treatment, with fever typically resolving within 48 to 72 hours. Complete clearance of parasites from the blood, confirmed by follow-up blood smear, usually follows within a few days more. If fever persists beyond 48–72 hours, or if the patient's condition worsens, this should prompt urgent reassessment for resistant infection, a different Plasmodium species, or a coexisting illness, rather than simply waiting longer for the drug to work.

Common side effects during short-course malaria treatment include nausea, stomach upset, headache, and dizziness; these are generally mild and dose-related. Rare but serious risks, more relevant to long-term use in autoimmune disease than short malaria courses, include effects on the retina and heart rhythm (QT prolongation), which is why hydroxychloroquine is used cautiously in patients with existing heart rhythm disorders or those taking other QT-prolonging drugs. As noted above, anyone with vivax or ovale malaria needs a frank conversation with their physician about follow-up treatment to prevent relapse, and anyone with severe symptoms — confusion, difficulty breathing, reduced urination, or inability to keep fluids down — needs emergency care, not outpatient antimalarial dosing.

Making an informed choice

The honest, evidence-based summary is this: hydroxychloroquine is a real, effective, well-studied treatment for malaria caused by chloroquine-sensitive parasites, and a legitimate weekly preventive option for travel to the specific regions where those sensitive strains still predominate. It is not the right choice for chloroquine-resistant falciparum malaria, which is now the more common threat across much of Africa, Southeast Asia, and the Amazon basin, and where artemisinin-based combination therapy is the appropriate first-line treatment. Anyone planning travel to a malarial region should discuss their specific itinerary with a physician or travel-medicine clinic well before departure, since the right preventive drug depends entirely on local resistance patterns — a decision best made with a doctor who knows the destination, the traveler's health history, and the most current regional data, rather than by assuming any single drug is universally correct.

Key takeaway: Hydroxychloroquine remains a genuinely effective, FDA-approved treatment for malaria caused by chloroquine-sensitive parasites, but it does not work against chloroquine-resistant strains and should only be used for malaria under a physician's guidance and species-specific diagnosis.